Pfizer and BioNTech to Supply the European Union With up to 1.8 Billion Additional Doses of COMIRNATY® Pharmaceutical Investing
Gilead-Kite Oncology to Present Transformative Science From Growing Portfolio at ASCO 2021 Biotech Investing
Long-Term Data from Pivotal KarMMa Study Continue to Demonstrate Deep and Durable Responses and Predictable Safety Profile with Bristol Myers Squibb and bluebird bio's Abecma in Relapsed or Refractory Multiple Myeloma Biotech Investing
Six-and-a-Half-Year Outcomes for Opdivo in Combination with Yervoy Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma Biotech Investing
Opdivo Plus Yervoy with Two Cycles of Chemotherapy Demonstrates Durable Overall Survival vs. Chemotherapy at Two Years in First-Line Non-Small Cell Lung Cancer in Phase 3 CheckMate -9LA Trial Biotech Investing
Bristol Myers Squibb Announces LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination Significantly Improves Progression-Free Survival vs. Opdivo in Patients with Previously Untreated Metastatic or Unresectable Melanoma Biotech Investing
Four-Year Data from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo Plus Yervoy in Patients with Non-Small Cell Lung Cancer with PD-L1 Expression ?1% Biotech Investing
